Early administration of heme arginate for acute porphyric attacks

Arch Intern Med. 1993 Sep 13;153(17):2004-8.


Background: We investigated the efficacy of early administration of heme arginate in acute porphyric attacks.

Methods: The series consisted of 51 consecutive acute attacks in 22 patients with acute intermittent porphyria and in two patients with variegate porphyria referred to a hospital in France or in Finland. Four attacks were associated with pareses, and 47 attacks were not. Heme in a dose of 250 mg or 3 mg/kg was started within 24 hours after admission in 37 (72.5%) of the attacks and within 4 days in 49 (96%) of the attacks. During all except five attacks, four daily infusions were given.

Results: The mean (+/- SD) duration of abdominal or nonabdominal pain was 2.5 +/- 0.97 days, and opiates were stopped an average of 2.8 +/- 0.72 days after the first heme infusion was started. All patients responded. In 46 (90%) of the attacks, the total hospitalization time was 7 days or less. The mean urinary excretion of porphobilinogen decreased to 16.2% +/- 7.7% and that of 5-aminolevulinic acid to 11.6% +/- 5.6% of pretreatment values. The only side effect was moderate thrombophlebitis in one patient.

Conclusion: Favorable responses in every attack suggest specific effects of heme. In patients with acute attacks, heme therapy should be started immediately on admission.

MeSH terms

  • Adult
  • Aged
  • Arginine / administration & dosage
  • Arginine / therapeutic use*
  • Female
  • Heme / administration & dosage
  • Heme / therapeutic use*
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Porphyria, Acute Intermittent / drug therapy*
  • Time Factors
  • Treatment Outcome


  • Heme
  • Arginine
  • heme arginate